White Paper

Expanded Access And Commercial Packaging Strategies For Orphan, Niche, And Low-Volume Drugs

Source: Catalent
medicine capsule blister package

Most commercial contract drug packagers do not provide consistent scheduling for low-volume drugs, which creates supply challenges. In fact, a drug packaging delay can create a market shortage that triggers serious health consequences for patients who rely on the drug. This issue can arise with niche and orphan drugs, as well as any other drugs packaged in small volumes. Conversely, a clinical supply partner can provide packaging as needed, plus handle distribution for expanded access and general commercial needs. This summary describes low-volume drugs, examines commercial packaging and supply challenges, and explores potential solutions.

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Drug Discovery Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: